Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Product

Sirolimus

Aliases
AY 22989, mTOR inhibitor, Optional Sirolimus, RAPA, Rapamune (8 other aliases)
Name
sirolimus
FDA Approved
Yes

51 clinical trials

19 organizations

1 drug

110 indications

4 documents

Indication
Frontotemporal Dementia
Indication
Complications of Renal Dialysis
Indication
End-Stage Renal Disease
Indication
Chronic Kidney Failure
Indication
Complication of Hemodialysis
Indication
Vascular Access Complication
Indication
Arteriovenous Fistula
Indication
Parkinson's disease
Indication
Gaucher's Disease
Indication
Type 2
Indication
Kidney Failure
Indication
Graft-Versus-Host Disease
Indication
Angiofibroma of Face
Indication
Tuberous Sclerosis
Indication
PEComa
Indication
Acute Lymphoblastic Leukemia
Indication
Myelodysplastic Syndromes
Indication
T-lymphoblastic lymphoma
Indication
Acute Lymphocytic Leukemia
Indication
Acute Myeloid Leukemia
Indication
Acute Biphenotypic Leukemia
Indication
Acute Undifferentiated Leukemia
Indication
Aplastic Anemia
Indication
Sickle Cell Anemia
Indication
Sickle Cell Disease
Indication
Thalassemia
Indication
Stem Cell Transplantation
Indication
Genetic Predisposition to Disease
Indication
Healthy Control Participants
Indication
Transplant Recipients
Indication
Skin Cancer
Indication
Malignant Peripheral Nerve Sheath Tumors
Indication
Neurofibromatosis type 1
Indication
Hematologic Neoplasms
Indication
Hematologic and Lymphocytic Disorder
Indication
Myelodysplastic Syndrome
Indication
Primary Myelofibrosis
Indication
Severe Combined Immune Deficiency
Indication
Alzheimer's disease
Indication
Extensive-stage small cell lung carcinoma
Indication
Adenocarcinoma of the Lung
Indication
Recurrent Non-Small Cell Lung Carcinoma
Indication
Small Cell Lung Carcinoma
Indication
Squamous Cell Lung Carcinoma
Indication
Congenital Hemolytic Anemia
Indication
Chronic Liver Disease
Indication
Stage IIIA Non-Small Cell Lung Cancer
Indication
Stage IIIB Non-Small Cell Lung Cancer
Indication
Stage IV Non-Small Cell Lung Cancer
Indication
Graft-Vs-Host Disease
Indication
Graft-versus-host disease
Indication
Kaposiform Hemangioendothelioma
Indication
Kasabach-Merritt Syndrome
Indication
Castleman Disease
Indication
Castleman's Disease
Indication
Multicentric
Indication
Acute
Indication
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Indication
Adult Acute Myeloid Leukemia With Del(5q)
Indication
Acute Myeloid Leukemia with inv(16)(p13;q22)
Indication
Acute promyelocytic leukemia
Indication
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Indication
Acute Myeloid Leukemia with t(8;21)(q22;q22)
Indication
Myelodysplastic Syndrome with Isolated Del(5q)
Indication
Adult Acute Myeloid Leukemia
Indication
Tufted Hemangioma
Indication
Lymphangioleiomyomatosis
Indication
Beta-thalassemia
Indication
Pulmonary Fibrosis
Indication
COVID-19 Pneumonia
Indication
Long COVID
Indication
Hemoglobinopathies
Indication
Diabetic Retinopathy
Indication
Microcystic Lymphatic Malformation
Indication
Vascular Malformation
Indication
Vascular Malformations
Indication
PTEN Gene Mutation
Indication
Cowden syndrome
Indication
Cowden Syndrome
Indication
Uveitis
Indication
Panuveitis
Indication
Vascular Anomalies
Indication
Metastatic dMMR Solid Cancer
Indication
Solid Tumor
Indication
Cancer
Indication
Metastatic Solid Tumor
Indication
Anaemia
Indication
Sickle Cell
Indication
Superficial Lymphatic Malformations
Indication
Germ Cell Tumor
Indication
yolk sac tumor
Indication
Vascular Anomaly
Indication
Biphenotypic Acute Leukemia
Indication
Prolymphocytic Leukemia
Indication
Chronic Myelogenous Leukemia
Indication
Plasma Cell Leukemia
Indication
Leukemia
Indication
myeloid
Indication
Myelodysplastic Syndrome With Excess Blasts-1
Indication
Burkitt lymphoma
Indication
Relapsed T-Cell Lymphoma
Indication
Chronic Lymphocytic Leukemia
Indication
Small Lymphocytic Lymphoma
Indication
Marginal Zone Lymphoma
Indication
Follicular Lymphoma
Indication
Myeloproliferative Neoplasm
Indication
Myelofibrosis
Indication
Beta Thalassemia
Indication
lymphatic malformation
Indication
Thyroid-Associated Ophthalmopathy
Drug
sirolimus
Clinical trial
A Phase 1/2 Ascending Dose Study to Evaluate the Safety and Effects on Progranulin Levels of LY3884963 in Patients With Fronto-Temporal Dementia With Progranulin Mutations (FTD-GRN)
Status: Recruiting, Estimated PCD: 2029-08-31
Clinical trial
A Phase 3, Prospective, Randomized, Multicenter, Single-blind, Controlled Study Evaluating Arteriovenous Fistula Outcomes With and Without a Perivascular Sirolimus Eluting Collagen Implant (The ACCESS 2 Trial)
Status: Recruiting, Estimated PCD: 2024-03-01
Clinical trial
A Phase 1/2a Open-Label Ascending Dose Study to Evaluate the Safety and Effects of LY3884961 in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)
Status: Recruiting, Estimated PCD: 2029-06-01
Clinical trial
An Open-label, Phase 1/2 Study to Evaluate the Safety and Efficacy of Single-dose LY3884961 in Infants With Type 2 Gaucher Disease
Status: Active (not recruiting), Estimated PCD: 2028-05-01
Clinical trial
Phase 2 Multi Center Prospective Rand. Double Blind Placebo Cont. Parallel Design Study to Evaluate Safety & Efficacy of Topical Sirolimus for Cutaneous Angiofibromas in Subjects W/ Tuberous Sclerosis Complex Followed by Opt. Open Label
Status: Terminated, Estimated PCD: 2023-03-24
Clinical trial
A Randomized, Open-label and Multicenter Trial Comparing Withdrawal of Steroids or Tacrolimus From Sirolimus-based Immunosuppressive Regimen in de Novo Renal Allograft Recipients
Status: Completed
Clinical trial
A Phase Ⅰb/Ⅱ Multi-center Study of Safety and Efficacy of Sirolimus for Injection (Albumin-bound) in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumor (PEComa)
Status: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers That Progressed on PD-1/PD-L1 Inhibitors
Status: Recruiting, Estimated PCD: 2026-06-30
Clinical trial
Sirolimus+Abatacept+Mycophenolate Mofetil Regimen for Prophylaxis of Acute Graft-versus-host Disease (aGvHD) in Patients Receiving Haploidentical Hematopoietic Stem Cell Transplantation (Haplo-HSCT) Who Are Intolerant to Calcineurin Inhibitor
Status: Not yet recruiting, Estimated PCD: 2024-06-01
Clinical trial
Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Severe Congenital Anemias Including Sickle Cell Disease and Beta-Thalassemia
Status: Active (not recruiting), Estimated PCD: 2018-08-01
Clinical trial
Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia in Individuals With Higher Risk of Transplant Failure
Status: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
Short Term Apolipoprotein E (ApoE)-Dependent Cerebral Blood Flow Response to Sirolimus in Cognitively Normal Adults
Status: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
A Randomised Double-blind Placebo-controlled Trial of Topical Sirolimus in Chemoprevention of Facial Squamous Cell Carcinomas in Solid Organ Transplant Recipients
Status: Not yet recruiting, Estimated PCD: 2026-05-15
Clinical trial
SARC031: A Phase 2 Trial of the MEK Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Combination With the mTOR Inhibitor Sirolimus for Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors
Status: Completed, Estimated PCD: 2022-06-22
Clinical trial
Phase I/II Study De-intensifying Exposure of Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HLA-haploidentical Hematopoietic Cell Transplantation for Hematologic Malignancies
Status: Recruiting, Estimated PCD: 2025-05-31
Clinical trial
Phase IIa Study of Addition of Itacitinib With Tacrolimus/Sirolimus Regimen for GVHD Prophylaxis in Fludarabine and Melphalan Non-Myeloablative Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, MDS or MF
Status: Active (not recruiting), Estimated PCD: 2023-05-22
Clinical trial
Matched Related and Unrelated Donor Stem Cell Transplantation for Severe Combined Immune Deficiency (SCID): Busulfan-based Conditioning With h-ATG, Radiation, and Sirolimus
Status: , Estimated PCD: 2026-09-09
Clinical trial
Evaluating Rapamycin Treatment in Alzheimer's Disease Using Positron Emission Tomography (ERAP)
Status: , Estimated PCD: 2025-01-31
Clinical trial
A Phase II Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease
Status: Recruiting, Estimated PCD: 2025-11-01
Clinical trial
Phase I Study of Escalating Doses of 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody Added to the Conditioning Regimen of Fludarabine, Melphalan and Organ Sparing Total Marrow and Lymphoid Irradiation (TMLI) as Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
Status: Not yet recruiting, Estimated PCD: 2027-02-24
Clinical trial
A Phase I-II Trial of Combined PKCι and mTOR Inhibition for Patients With Advanced or Recurrent Lung Cancer (NSCLC and SCLC) Without Standard Treatment Options
Status: Completed, Estimated PCD: 2023-04-24
Clinical trial
Nonmyeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Severe Congenital Anemias Including Sickle Cell Disease (SCD) and B-Thalassemia
Status: Active (not recruiting), Estimated PCD: 2023-01-20
Clinical trial
REpurposing SirolimUS in Compensated Advanced Chronic Liver Disease. The RESUS Proof of Concept Study
Status: Active (not recruiting), Estimated PCD: 2024-07-31
Clinical trial
A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression
Status: Completed, Estimated PCD: 2022-01-28
Clinical trial
Guided Discontinuation Versus Maintenance Treatment of Sirolimus in Pediatric Patients With Kaposiform Hemangioendothelioma: a Randomized Controlled Trial
Status: Completed, Estimated PCD: 2023-02-01
Clinical trial
A Phase II, Single-arm Open-label Multi-center Study of Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease
Status: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease
Status: Completed, Estimated PCD: 2023-09-01
Clinical trial
A Phase II Study of Azacitidine and Sirolimus for the Treatment of High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Refractory to or Not Eligible for Intensive Chemotherapy
Status: Active (not recruiting), Estimated PCD: 2028-04-19
Clinical trial
A Randomized Phase 2 Study of Vincristine Versus Sirolimus to Treat High Risk Kaposiform Hemangioendothelioma (KHE).
Status: Terminated, Estimated PCD: 2019-10-02
Clinical trial
Multicenter Interventional Lymphangioleiomyomatosis (LAM) Early Disease Trial
Status: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
Efficacy and Safety of High- vs Low-Dose Sirolimus in Patients With Kaposiform Hemangioendothelioma: A Trial Protocol
Status: Completed, Estimated PCD: 2023-08-10
Clinical trial
Addition of JSP191 (C-kit Antibody) to Non-myeloablative Hematopoietic Cell Transplantation For Sickle Cell Disease and Beta-Thalassemia
Status: Recruiting, Estimated PCD: 2032-11-01
Clinical trial
SECOVID: A Multi-center, Randomized, Dose-ranging Parallel-group Trial Assessing the Efficacy of Sirolimus in Hospitalized Patients With COVID-19 Pneumonia for the Prevention of Post-COVID Fibrosis
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Randomized Controlled Double-Blind Trial of Sirolimus for Improving Social Abilities in People With PTEN Germline Mutations
Status: Not yet recruiting, Estimated PCD: 2028-06-01
Clinical trial
Sickle Cell Disease Transplant Using a Nonmyeloablative Approach: Adding Daratumumab for Patients With Anti-donor Red Cell AntibodY
Status: Recruiting, Estimated PCD: 2044-09-01
Clinical trial
A Randomized Trial of Sirolimus (Rapamune(R)) for Relapse Prevention in Patients With Severe Aplastic Anemia Responsive to Immunosuppressive Therapy
Status: Recruiting, Estimated PCD: 2024-08-31
Clinical trial
Multicenter International Lymphangioleiomyomatosis Efficacy and Safety of Sirolimus Trial
Status: Completed, Estimated PCD: 2010-09-01
Clinical trial
A Non-Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched and HLA-Matched Bone Marrow for Patients With Sickle Cell Disease and Other Hemoglobinopathies
Status: Active (not recruiting), Estimated PCD: 2023-11-01
Clinical trial
Pilot Study of the Evaluation of Sirolimus in the Treatment of Diabetic Macular Edema
Status: Completed, Estimated PCD: 2011-01-01
Clinical trial
Role of Sirolimus in Treatment of Microcystic , Mixed Lymphatic and Vascular Malformations
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
Sirolimus as a Therapeutic Approach for Uveitis: A Phase 2, Open-label, Randomized Study to Assess the Safety, Tolerability, and Bioactivity of Two Doses of Intravitreal Injection of Sirolimus in Patients With Non-infectious Uveitis
Status: Withdrawn, Estimated PCD: 2024-09-01
Clinical trial
Treatment Protocol for the Use of the Topical Rapamycin/Sirolimus for Complicated Vascular Anomalies and Other Susceptible Lesions
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Percutaneous Administration of Sirolimus in the Treatment of Superficial Complicated Vascular Anomalies: a Randomized Controlled Trial
Status: Recruiting, Estimated PCD: 2025-11-01
Clinical trial
Phase II Study to Evaluate the Efficacy and Safety of Sirolimus in Subjects With Metastatic, Mismatch Repair Deficient Solid Tumors After Immunotherapy
Status: Terminated, Estimated PCD: 2023-05-16
Clinical trial
Siplizumab-based Conditioning for Hematopoietic Stem Cell Transplantation in Patients With Advanced Sickle Cell Disease (CD2 SCD)
Status: Recruiting, Estimated PCD: 2028-07-01
Clinical trial
Clinical Study of Sirolimus Combined With Chemotherapy in the Treatment of Recurrent/Refractory Yolk Sac Tumor in Children
Status: Completed, Estimated PCD: 2024-01-01
Clinical trial
Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning (RIC) With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases
Status: Recruiting, Estimated PCD: 2027-10-22
Clinical trial
A Personalized Medicine Approach for Beta-thalassemia Transfusion Dependent Patients: Testing SIROLIMUS in a First Pilot Clinical Trial
Status: Completed, Estimated PCD: 2022-04-30
Clinical trial
0.1% Topical Sirolimus in the Treatment of Cutaneous Microcystic Lymphatic Malformations in Children and Adults: Phase II, Split-body Randomized, Double-blind, Vehicle-controlled Clinical Trial
Status: Recruiting, Estimated PCD: 2023-09-01
Clinical trial
Prospective Comparison of Sirolimus Against Corticosteroids in Treatment of Patients With Active Thyroid Eye Disease
Status: Recruiting, Estimated PCD: 2026-01-01
Clinical trial
Discovery of Sirolimus Sensitive Biomarkers in Blood
Status: Recruiting, Estimated PCD: 2025-09-30
Organization
Zydus Pharmaceuticals USA Inc.
Organization
Apotex Corp.
Organization
Major Pharmaceuticals
Organization
Ascend Laboratories, LLC
Document
DailyMed Label: sirolimus
Organization
Novadoz Pharmaceuticals LLC
Organization
NORTHSTAR RX LLC
Organization
Greenstone LLC
Organization
Zydus Lifesciences Limited
Organization
Glenmark Pharmaceuticals Inc., USA
Document
DailyMed Label: Rapamune
Organization
Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.
Document
DailyMed Label: FYARRO
Organization
Aadi Bioscience
Organization
Amneal Pharmaceuticals NY LLC
Organization
REMEDYREPACK INC.
Organization
VistaPharm, LLC
Document
DailyMed Label: HYFTOR
Organization
Nobelpharma America, LLC
Organization
AvPAK
Organization
Dr. Reddy's Laboratories Limited
Organization
Apotex Corp
Organization
American Health Packaging